The absence of serum C3 and C4 complement assays and ANA and dsDNA antibodies, at onset or dynamically, represented a limitation in the systematic evaluation of the patient, not only for early diagnosis but also for assessing the evolutionary phases of SLE: active or latent. The gene discussed is BTG3; the disease is systemic lupus erythematosus.